Motif Bio PLC Appointment of IR Adviser

TIDMMTFB

Motif Bio PLC

02 September 2015

2 September 2015

Motif Bio plc

("Motif" or the "Company")

Motif Appoints Westwicke Partners as Investor Relations Adviser in U.S.

Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that it has appointed Westwicke Partners as its investor relations adviser in the U.S. Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to public and private companies in the healthcare sector.

Graham Lumsden, CEO of Motif, said: "We look forward to building a relationship with the Westwicke team and to leveraging their experience as we continue to move our clinical development programs forward".

Enquiries

 
 Motif Bio plc                           info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  Robert Bertoldi (Chief Financial 
  Officer) 
  www.motifbio.com 
 
 Zeus Capital Limited (NOMINATED         +44 (0) 20 
  ADVISER AND BROKER)                     7533 7727 
 Phil Walker/ John Treacy 
  Dominic Wilson 
 Northland Capital Partners Limited      +44 (0) 20 
  (BROKER)                                7382 1100 
 Patrick Claridge/ David Hignell 
  John Howes/ Mark Treharne (Broking) 
 
                                           +49 (0) 89 
                                           210 2280 
  MC Services AG (TRADE PR)                +44 (0) 207 
    Raimund Gabriel                        148 5998 
    Shaun Brown 
 
 
  Plumtree Capital Limited (FINANCIAL      +44 (0) 207 
  ADVISOR)                                 183 2493 
 Stephen Austin 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Dominic Barretto 
  Philip Ranger                          +44 (0) 7768 
  Charles Goodwin                         537 739

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.

About Westwicke Partners

Westwicke Partners provides strategic investor relations and capital markets advisory services exclusively to healthcare companies. With offices in Baltimore, Boston, San Francisco and San Diego, the firm works with over 80 public and private companies across all subsectors of healthcare. Services provided by Westwicke include corporate messaging and positioning, investor presentation review, sell side relationship building, buy side targeting, earnings call preparation, capital markets advisory, pre-IPO planning and execution, and investor day meetings. All of Westwicke's senior professionals have extensive Wall Street experience as former sell side and buy side research analysts, portfolio managers, investment bankers, institutional sales people, and equity capital markets professionals. The firm works with its clients to help position their story properly within the investment community, raise their visibility on Wall Street, and develop value-added strategies to build a quality, long-term shareholder base and enhance equity market value. For additional information about Westwicke please visit www.westwicke.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUGUPWBUPAUAP

(END) Dow Jones Newswires

September 02, 2015 02:00 ET (06:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024